<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ren W</submitter><funding>Tenth Youth Fund of the First Hospital of Jilin University</funding><funding>Jilin Provincial Department of science and technology</funding><pagination>5609</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9457787</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(17)</volume><pubmed_abstract>The TDM of voriconazole which exhibits wide inter-individual variability is indispensable for treatment in clinic. In this study, a method that high-performance liquid chromatography tandem mass spectrometry cubed (HPLC-MS&lt;sup>3&lt;/sup>) is first built and validated to quantify voriconazole in human plasma. The system is composed of Shimadzu Exion LC&lt;sup>TM&lt;/sup> UPLC coupled with a Qtrap 5500 mass spectrometer. The separation of voriconazole is performed on a Poroshell 120 SB-C18 column at a flow rate of 0.8 mL/min remaining 7 min for each sample. The calibration curves are linear in the concentration range of 0.25-20 μg/mL. Intra-day and inter-day accuracies and precisions are within 8.0% at three concentrations, and the recoveries and matrix effect are all within accepted limits. In terms</pubmed_abstract><journal>Molecules (Basel, Switzerland)</journal><pubmed_title>Comparison of LC-MS&lt;sup>3&lt;/sup> and LC-MRM Method for Quantifying Voriconazole and Its Application in Therapeutic Drug Monitoring of Human Plasma.</pubmed_title><pmcid>PMC9457787</pmcid><funding_grant_id>JDYY102019019</funding_grant_id><funding_grant_id>20200404167YY</funding_grant_id><pubmed_authors>Zhang G</pubmed_authors><pubmed_authors>Ren W</pubmed_authors><pubmed_authors>Zhai T</pubmed_authors><pubmed_authors>Huang J</pubmed_authors><pubmed_authors>Yin L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparison of LC-MS&lt;sup>3&lt;/sup> and LC-MRM Method for Quantifying Voriconazole and Its Application in Therapeutic Drug Monitoring of Human Plasma.</name><description>The TDM of voriconazole which exhibits wide inter-individual variability is indispensable for treatment in clinic. In this study, a method that high-performance liquid chromatography tandem mass spectrometry cubed (HPLC-MS&lt;sup>3&lt;/sup>) is first built and validated to quantify voriconazole in human plasma. The system is composed of Shimadzu Exion LC&lt;sup>TM&lt;/sup> UPLC coupled with a Qtrap 5500 mass spectrometer. The separation of voriconazole is performed on a Poroshell 120 SB-C18 column at a flow rate of 0.8 mL/min remaining 7 min for each sample. The calibration curves are linear in the concentration range of 0.25-20 μg/mL. Intra-day and inter-day accuracies and precisions are within 8.0% at three concentrations, and the recoveries and matrix effect are all within accepted limits. In terms</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-18T18:24:34.949Z</modification><creation>2025-04-07T06:01:42.933Z</creation></dates><accession>S-EPMC9457787</accession><cross_references><pubmed>36080374</pubmed><doi>10.3390/molecules27175609</doi></cross_references></HashMap>